公开(公告)号：EP3900725A1

公开(公告)日：2021-10-27

申请号：EP19899095.4

申请日：2019-12-19

Applicant: Korea Basic Science Institute

Inventor： KIM, Gun Hwa ,  LEE, Min Ji ,  KIM, Koon Soon ,  CHUNG, Hyo Kyun ,  LEE, Ji Hoon ,  JUNG, Se Jin ,  KIM, Da Rong

IPC: A61K31/496 ,  A61P3/10 ,  A61P1/16 ,  A23L33/10

Abstract: The present invention relates to a composition comprising a CYP4A-inhibiting compound as an active ingredient for preventing or treating metabolic diseases, more specifically to a composition comprising the compound expressed by chemical formula 1 of the present invention or pharmaceutically acceptable salt thereof as an active ingredient for preventing, ameliorating or treating metabolic diseases.

公开(公告)号：EP3406250B1

公开(公告)日：2020-03-18

申请号：EP18173590.3

申请日：2018-05-22

Applicant: Korea Basic Science Institute

Inventor： KIM, Gun Hwa ,  PARK, Joo Hyun ,  LEE, Min Ji

IPC: A61K31/4545 ,  A61K31/538 ,  A61P1/16 ,  A61P3/10

公开(公告)号：EP3406250A1

公开(公告)日：2018-11-28

申请号：EP18173590.3

申请日：2018-05-22

Applicant: Korea Basic Science Institute

Inventor： KIM, Gun Hwa ,  PARK, Joo Hyun ,  LEE, Min Ji

IPC: A61K31/4545 ,  A61K31/538 ,  A61P1/16 ,  A61P3/10

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes or fatty liver comprising a CYP4A (cytochrome P450A) inhibitor as an active ingredient. The compound of the present invention has activities of promoting glucose uptake into hepatocytes, inhibiting fat accumulation in liver cells, and inhibiting reactive oxygen production in mitochondria, and thus can be very usefully used for the development of a therapeutic agent for diabetes or fatty liver.